查找临床试验
已按「子宫内膜癌」检索，对应国际通用词 endometrial cancer
共找到 77 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 23:03，每 5 分钟自动同步An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
China
年龄 18 Years – 不限
Beijing Tide Pharmaceutical Co., Ltd
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
China
年龄 18 Years – 75 Years
Sichuan Baili Pharmaceutical Co., Ltd.
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
China
年龄 18 Years – 不限
Peking University First Hospital
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
United States、Argentina、Chile、China、France 等 12 国
年龄 18 Years – 不限
Daiichi Sankyo
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
China
年龄 18 Years – 不限
GlaxoSmithKline
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
China
年龄 不限 – 40 Years
West China Second University Hospital
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
China
年龄 18 Years – 75 Years
Sichuan Baili Pharmaceutical Co., Ltd.
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
United States、Argentina、Australia、Belgium、Brazil 等 12 国
年龄 18 Years – 不限
Daiichi Sankyo
Study of GV20-0251 in Participants With Solid Tumor Malignancies
China
年龄 18 Years – 不限
GV20 Therapeutics
Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer
China
年龄 17 Years – 45 Years
Peking University People's Hospital
Liquid Biopsy-Based Early Screening for Endometrial Cancer in Regional Chinese Populations
China
年龄 不限 – 18 Years
Guizhou Provincial People's Hospital
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
China
年龄 18 Years – 不限
Shenzhen Ionova Life Sciences Co., Ltd.